C3 Jian’s C16G2 is a synthetic peptide derived from the company’s pheromone signaling platform technology referred to as STAMPs (specifically targeted antimicrobial peptides). The drug targets the specific elimination of Streptococcus mutans, which is believed to be a critical factor in the cause of dental caries or tooth decay.
The STAMP technology has potential applications to a variety of diseases and disorders particularly related to bacterial and fungal infections. This technology has the ability to identify peptide sequences that specifically target most types of bacteria.
C16G2 is being developed for the prevention of dental caries in adults, adolescents and pediatrics.
The Phase II study is a double-blind, safety and microbiology study in healthy adult subjects. Primary objective of the placebo-controlled, four arm, Phase II clinical trial is to further build on the safety profile of C16G2 administration in both dental gel and mouth rinse dosages.
The randomized study will also focus on targeting antimicrobial activity of these applications by measuring the reduction of Streptococcus mutans, as well as the total bacteria in dental plaque and saliva. With proper safety, the company expects to extend the Phase II program to assess C16G2 in children.
C3 Jian president and CEO Todd R Patrick said: "The advancement of the Phase 2 clinical program for C16G2 is a testament to our development team’s talent and the potential of the STAMP technology platform."
C3 Jian anticipates completion of the Phase II study in late 2014.